Shares of Hims & Hers were on fire Monday because the FDA's new leader seems to be a fan of the company's business model.

Canaccord raised the firm’s price target on Hims & Hers to $38 from $28 and keeps a Buy rating on the shares. The stock rallied 70% in ...

Hims & Hers achieved a 44% YoY increase in Q3 2024, surpassing 2 million active users. Find out what positions HIMS as a key ...

On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $32.15 which represents a slight increase of $1.81 or 5.97% from the prior close of $30.34. The stock opened at ...

Hims & Hers' financials are robust, with strong and accelerating revenue growth, growing free cash flow, manageable SBC, and ...

Hims & Hers Health Inc. shares surged 24% to close at fresh record after Hunterbrook Media said the company is poised to be a ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...

Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Hims & Hers (HIMS) is up 14.0%, or $4.29 to $34.97.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium ...